Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: A useful strategy to maximize surgical resection

Neurologia Medico-Chirurgica

Volumn 50, Issue 5, 2010, Pages 410-413

  Giannantonio, Spena ^a   Diego, Garbossa ^a   Laura, Barletta ^a   Prevost, Chiara ^a   Pietro, Versari ^a  

^a Civil Hospital   (Italy)

Author keywords

Brain mapping; Chemotherapy; Infiltrative tumor; Low grade glioma; Surgery

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMOZOLOMIDE;

ADULT; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CASE REPORT; CELL INFILTRATION; CELL PROLIFERATION; CRANIOTOMY; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE LOCUS; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE PERIOD; PYRAMIDAL TRACT; TUMOR BIOPSY; TUMOR LOCALIZATION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CORPUS CALLOSUM; DACARBAZINE; FEMALE; FRONTAL LOBE; FUNCTIONAL LATERALITY; HUMANS; MOTOR CORTEX; NEOADJUVANT THERAPY; PREOPERATIVE PERIOD; TREATMENT OUTCOME;

EID: 77953437754     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.50.410     Document Type: Article

References (29)

1. Berger MS, Deliganis AV, Dobbins JD, Keles GE: The effect of extent of resection on recurrence in patients with low-grade cerebral hemisphere gliomas. Cancer 74: 1784-1791, 1994
2. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14: 1715-1721, 2003
3. Buckner JC, Gesme D Jr, O'Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R: Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21: 251-255, 2003
4. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD: Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 22: 427-435, 2004
5. Duffau H, Lopes M, Arthuis F, Bitar A, Sichez JP, Van Effenterre R, Capelle L: Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985-1996) and with (1996-2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry 76: 845-851, 2005
6. Duffau H, Taillandier L, Capelle L: Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma. J Neurooncol 80: 171-176, 2006
7. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998
8. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Criniere E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broet P, Sanson M, Delattre JY: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22: 3133-3138, 2004
9. Hwang YY, Moon H, Cho SH, Kim KT, Moon YJ, Kim SR, Kim DS: Ten-year survival of patients with locally advanced Stage Ib-IIb cervical cancer after neoadjuvant chemotherapy and radical hysterectomy. Gynecol Oncol 82: 88-93, 2001
10. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K: Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68: 1831-1836, 2007
11. Keles GE, Lamborn KR, Berger MS: Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 95: 735-745, 2001
12. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW, Dekker AW, Jolles J, Slotman BJ, Struikmans H, Taphoorn MJ: Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360(9343): 1361-1368, 2002
13. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, Lonjon M, Fauchon F, Paquis P, Frenay M: Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 14: 391-398, 2007
14. Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T: Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106: 1759-1765, 2006
15. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 46: 203-207,1996
16. Mosharafa AA, Foster RS, Leibovich BC, Bihrle R, Johnson C, Donohue JP: Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 169: 2126-2128, 2003
17. Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM: Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14: 1722-1726, 2003
18. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, ffronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS: Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21: 646-651, 2003
19. Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, Friedman AH, Bigner DD, Bigner SH, McLendon RE: Molecular markers of prognosis in astrocytic tumors. Cancer 94: 2688-2697, 2002
20. Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY: Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61: 484-490, 2007
21. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS: Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26: 1338-1345, 2008
22. Soffietti R, Nobile M, Ruda R, Borgognone M, Costanza A, Laguzzi E, Mutani R: Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. Cancer 100: 807-813, 2004
23. Soffietti R, Ruda R, Bradac GB, Schiffer D: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43: 1066-1073, 1998
24. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103: 802-809, 2005
25. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D: Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 64: 271-278, 2003
26. van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51: 1140-1145, 1998
27. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht ChJ, Allgeier A, Gorlia T; European Organization for Research and Treatment of Cancer Brain Tumor Group: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21: 2525-2528, 2003
28. Walker C, Haylock B, Husband D, Joyce KA, Fildes D, Jenkinson MD, Smith T, Broome J, Kopitzki K, du Plessis DG, Prosser J, Vinjamuri S, Warnke PC: Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms. Br J Cancer 95: 1424-1431, 2006
29. Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A: Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2: 395-403, 2003